Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IDH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IDH1 WT & Mutant (R132H/R132C/R132S/R132G) Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View IDH1 Products |
| Gene Delivery | IDH1 Promise-ORF / Lentivirus Full-length ORF for stable mutant cell lines. |
View IDH1 Products |
| Benchmark Ab | Anti-IDH1 (R132H Specific) Sequence Verified recombinant positive control for IHC/WB. |
View IDH1 Products |
| Validator | IDH1 siRNA Set For specific knockdown verification in cell lines. |
View IDH1 Products |
| Related Target A | IDH2 Isoform counter-screening and dual-inhibition targeting. |
View IDH2 Products |
| Related Target B | TET2 Downstream epigenetic target affected by 2-HG accumulation. |
View TET2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs. Wild-Type Selectivity | Comprehensive panel of IDH1 mutants (R132H, R132C, R132S, R132G) and WT proteins available with >95% purity for precision enzymatic assays. Matched pair of WT and R132H proteins (SEC verified) for orthogonal selectivity screening. |
| Isoform Cross-Reactivity (IDH1 vs IDH2) | High-purity IDH2 WT and mutant homolog proteins (including R140Q, R172K) strictly verified by mass spectrometry for reliable counter-screening. |
| Acquired Resistance Profiling | Expanded IDH1 mutant panel (R132C, R132G, R132S, R132L) covering clinical resistance spectra for next-generation inhibitor screening. |
| Species Translation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with identical purity standards (>95%) for preclinical PK/PD evaluation. |
| Detection & Cellular Controls | Sequence-verified mutant-specific recombinant antibodies for assay benchmarking. High-efficiency siRNA and IDH1 ORF Lentivirus (R132H) for generating stable isogenic lines and target-specificity validation. |
Live IDH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IDH1 therapeutics is intensifying. First-generation inhibitors (ivosidenib, olutasidenib) have established standard of care in AML and cholangiocarcinoma. Servier's vorasidenib (Voranigo), a brain-penetrant dual IDH1/2 inhibitor, recently expanded the landscape into low-grade glioma, answering a critical need for CNS-active therapies. As acquired resistance mutations (R132C, R132G, R132S, R132L) emerge in relapsed patients, the next wave of R&D focuses on next-generation allosteric inhibitors with broader mutant coverage, rational combination regimens with hypomethylating agents (azacitidine) or BCL-2 inhibitors (venetoclax), and novel modalities such as PROTACs and mutant neoantigen vaccines. TarMart supports this evolution with precision mutant proteins that enable differentiation between wild-type inhibition liabilities and mutant-specific potency, as well as species orthologs for translational studies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Servier (Ivosidenib), Rigel/Forma (Olutasidenib) | AML, Cholangiocarcinoma | Mutant vs WT Selectivity Assay (Need high-purity R132H and WT proteins) |
| Brain-Penetrant Inhibitor | Servier (Vorasidenib) | Low-Grade Glioma, Astrocytoma | Dual IDH1/2 Specificity Profiling (Need IDH1 & IDH2 recombinant proteins) |
| Combination Regimen | BMS, AbbVie, Agios/Servier | AML, MDS | Synergy & 2-HG Inhibition Assay (Need stable mutant cell lines via lentivirus) |
| PROTAC / Degrader | Preclinical Biotech | Refractory AML / Solid Tumors | Ternary Complex & Target Engagement (Need full-length ORF and mutant proteins) |
| Vaccine / TCR-T | Bayer, Transgene, Nouscom | Glioma (Mutant Neoantigen) | Peptide Presentation (Need sequence-verified antigen control) |